ClinicalTrials.gg
Not yet recruitingNCT07871773Updated Oct 13, 2026

Food Is Medicine In Survivorship (Foodiis-AYA): Examining The Feasibility And Acceptability Of A Remotely-Delivered Meal Kit And Culinary Medicine Program For Survivors Of Adolescent/Young Adult (AYA) Cancer

An interventional study of Meal Preps and Questionnaire in Survivorship, Meal Kit and Culinary Medicine, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

Updated Oct 13, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 25 Years
Sex
All
01

Study summary

To study the feasibility of a new nutritional intervention (Food is Medicine in Survivorship - Adolescents / Young Adults [FoodiiSAYA]) for patients 18-25 years old who have completed cancer treatment.

Read the detailed description

Primary Objectives To examine the feasibility of FoodiiS-AYA, a scalable Food is Medicine intervention including brief digital culinary medicine education and healthy meal kit delivery targeting AYA cancer survivors aged 18-25 years.

02

Conditions studied

  • Survivorship
  • Meal Kit
  • Culinary Medicine
03

In context

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,044 studies on the registry; 578 are open to participants now.

Of its 608 completed or terminated interventional studies of FDA-regulated products, 407 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria

  • Currently aged 18-25 years
  • History of cancer diagnosed between the ages of 15-25
  • Have completed active cancer treatment (chemotherapy, radiation, immunotherapy, surgery)
  • Self-report having internet access.
  • Self-report as being able to speak and read English.
  • Self-report having access to a kitchen and refrigerator
  • Willing to complete study assessments.

Exclusion Criteria

  • Individuals under 18 or over 25 years old at the time of study enrollment
  • Currently undergoing active cancer treatment for recurrent or new primary cancer
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Foodiis Intervention

    Intervention includes videos, recipes, and other online healthy eating content.

    Other: Meal Preps · Other: Questionnaire

Interventions

  • OtherMeal Preps

    You will have a meal kit delivered to your home every month (Weeks 1, 5, and 9) during the 3-month program period. Each kit will include ingredients for making a healthy, nutritious meal.

  • OtherQuestionnaire

    You will be asked to complete another series of questionnaires. These will include several of the questionnaires you filled out at baseline, along with another short survey

06

What researchers measure

Primary outcomes

  1. Safety and adverse events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
    • Margaret Raber, DrPH · Contact · MPRaber@mdanderson.org · 713-563-8768
    • Margaret Raber, DrPH · Principal investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Jul 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 13, 2026
StartEst.
Mar 16, 2027
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871773
Collaborators
Cancer Prevention Research Institute of Texas
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Mar 16, 2027 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Margaret Raber, DrPH
Contact
MPRaber@mdanderson.org
713-563-8768
Margaret Raber, DrPH
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion